Recombinant Human Apolipoprotein A-I Protein, CF

Catalog #: 3664-AP Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
3664-AP-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

All Apolipoprotein A-I/ApoA1 Proteins and Enzymes

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Apolipoprotein A-I Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein A‑I/ApoA1 is immobilized at 5 µg/mL (100 µL/well), the concentration of Recombinant Human SR‑AI/MSR (Catalog # 2708-MS) that produces 50% of the optimal binding response is approximately 0.5‑2.5 µg/mL.

Source

E. coli-derived human Apolipoprotein A-I/ApoA1 protein
Asp25-Gln267, with an N-terminal Met and 6-His tag

Accession #

P02647

N-terminal Sequence
Analysis

Met-His

Predicted Molecular Mass

29 kDa

SDS-PAGE

27 kDa, reducing condiitons

Product Datasheets

3664-AP

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3664-AP

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: Apolipoprotein A-I/ApoA1

Apolipoprotein A1 (ApoA1) is a 28 kDa glycoprotein that is the major protein component of high density lipoprotein (HDL) particles. HDL particles play a central role in the reverse transport of cholesterol from peripheral tissues to the liver. HDL is known as “good cholesterol” due to its ability to facilitate the removal of cholesterol from macrophage foam cells in atherosclerotic plaques and thereby retard the progression of disease (1, 2). ApoA1 is secreted from hepatocytes with variable amounts of lipidation (3). Disc‑like HDL particles increase in size and adopt a spherical shape as they are loaded with additional lipids and cholesterol by ABC family transporters (4, 5). HDL particle interaction with lipid‑supplying cells is mediated by ApoA1 binding to the scavenger receptor SR‑A1 (6). HDL particles are further modified by the circulating enzymes LCAT (which converts cholesterol to cholesteryl esters), CETP (which transfers cholesteryl esters to LDL/VLDL particles), and PLTP (which transfers phospholipids from HDL to LDL/VLDL particles) (2). Upon HDL particle return to the liver, ApoA1 binds to the scavenger receptor SR‑B1 and the beta chain of ATP synthase on hepatocytes (7, 8). Hepatocytes internalize the particles and pass the cholesterol into bile for excretion. Polymorphisms of ApoA1 are associated with dysregulation of HDL levels and cholesterol homeostasis (1, 9). ApoA1 is catabolized in the kidney following its binding to Cubulin on renal proximal tubule epithelial cells (10). ApoA1, either as a free molecule or in lipidated particulate form, induces the release of insulin from pancreatic islets in a process that is dependent on ABCA1 and SR‑B1 (11). Mature human ApoA1 shares 65% and 62% aa sequence identity with mouse and rat ApoA1, respectively.

References